Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study

University of Sao Paulo

Status and phase: Completed; Phase 3

Conditions: Diabetic Macular Edema

Treatments: Drug: intravitreal bevacizumab injection(1.25mg)

Study type: Interventional

Funder types: Other

Identifiers

NCT02308644

80838792A

Details and patient eligibility

About

To evaluate the effects on contrast sensitivity (CS) measurements of intravitreal bevacizumab injections associated with standard metabolic control in eyes with diabetic macular edema (DME) associated with standard metabolic control.

Full description

Prospective, randomized, masked and interventional study. Patients with diabetes mellitus (DM) 2, glycated hemoglobin (HbA1c) less than 11% and previously treated macular edema three months before will be randomized in two groups. The baseline examination consisted of visual acuity (VA), CS using the Pelli-Robson Charts, optical coherence tomography (OCT) and Fluorescein Angiography for all eyes.

The same tests will be repeated above, in both groups, again, in the week 2,6 and 12, when the data is then collected for analysis and so ended the closed phase. On the same day will start the open phase, which will be applied intravitreal injection of bevacizumab in both groups and the same tests of closed phase will be held in the week 14,18 and 24 when the study will be completed then [Table 1] .

Patients will be monitored and controlled clinically including blood pressure measurements, laboratory blood tests such as blood glucose, glycated hemoglobin, urea, creatinine, total cholesterol and fractions.

Enrollment: 41 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age at least 18 years old, of both genders;
• Patients with diabetes mellitus type I or type II;
• Macular edema presence of clinically significant diabetic in their mixed or diffuse;
• Visual acuity worse than 20/40 corrected (< 68 letters ETDRS)
• Glycated hemoglobin ≤ 11%;
• Systolic and diastolic blood pressure < 170 and < 100 mmHg, respectively;
• Women not pregnant;
• Free and informed consent term signed the screening visit;
• Ability to adhere to the visits.

Exclusion criteria

• Failure to comply with any of the inclusion criteria;
• Treatment for DME within the prior 3 months;
• Vitreoretinal traction within 1 disc diameter (DD) of the fovea, clinically confirmed or with OCT;
• Atrophy or fibrosis surrounding the fovea;
• Any level of cataract;
• Vitreous hemorrhage or any opacity means;
• Eye disease related to diabetic retinopathy that can derail the central vision (eg Age Macula Degeneration, chorioretinitis scar, ...)
• Best-corrected visual acuity to 20/40 (> 68 letters ETDRS)
• Inability to understand the treatment and the term of consent;
• Debilitating systemic disorders that preclude the patient's admission to the study, according to the clinical judgment of the investigator;

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

41 participants in 2 patient groups

Bevacizumab

Experimental group

Description:

Group 1 - 21 eyes treated with intravitreal bevacizumab injection (1.25mg) at the weeks 0, 6,12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)

Treatment:

Drug: intravitreal bevacizumab injection(1.25mg)

Sham

Sham Comparator group

Description:

Group 2 - 20 eyes treated with sham injection at weeks 0 and 6; and intravitreal bevacizumab injection(1.25mg) in the weeks 12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)

Treatment:

Drug: intravitreal bevacizumab injection(1.25mg)